デフォルト表紙
市場調査レポート
商品コード
949518

エソメプラゾールの世界市場:2020-2026年

Global Esomeprazole Market 2020-2026

出版日: | 発行: Orion Market Research Pvt Ltd | ページ情報: 英文 | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=114.72円
エソメプラゾールの世界市場:2020-2026年
出版日: 2020年06月03日
発行: Orion Market Research Pvt Ltd
ページ情報: 英文
納期: 2-3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界のエソメプラゾール市場は、2020年から2026年の予測期間中、穏やかな成長率を示すと予想されます。エソメプラゾールは、Nexiumのブランド名で米国FDAからAstraZeneca plcに最初に承認されました。胃食道逆流症(GERD)の高い発生率は、世界的な市場成長の主な要因の1つです。 2017年、米国では、エソメプラゾールだけで約900万回処方されました。ただし、処方数は2011年以降継続的に減少しています。エソメプラゾールの代替薬の存在は、市場成長の主要な抑制要因の1つです。エソメプラゾールの化学異性体であるオメプラゾールは、エソメプラゾールの最も一般的な代替品の1つです。

当レポートでは、世界のエソメプラゾール市場について調査分析し、市場概要、市場成長への影響要因、市場規模と予測、セグメント別の市場分析、地域・国別の市場分析、競合情勢などについて、体系的な情報を提供しています。

目次

第1章 レポートの概要

第2章 市場概要および考察

  • 調査範囲
  • アナリストの考察&現在の市場動向
  • 規則&規制

第3章 競合情勢

  • 企業シェア分析
  • 主要戦略分析
  • 主要企業分析
    • AbbVie Inc
    • Sanofi SA
    • Mylan NV
    • Novartis AG
    • Teva Pharmaceutical Industries Ltd.

第4章 市場決定要因

  • 促進要因
  • 抑制要因
  • 機会

第5章 市場セグメンテーション

  • 世界のエソメプラゾール市場:疾患別
    • びらん性食道炎
    • 胃食道逆流症
    • ヘリコバクターピロリ菌感染症
    • その他
  • 世界のエソメプラゾール市場:タイプ別
    • ブランド医薬品
    • ジェネリック医薬品
  • 世界のエソメプラゾール市場:投薬タイプ別
    • カプセル・錠剤
    • 注射
    • その他(サスペンション/懸濁液)

第6章 地域分析

  • 北米
    • 米国
    • カナダ
  • 欧州
    • 英国
    • ドイツ
    • イタリア
    • スペイン
    • フランス
    • その他欧州
  • アジア太平洋
    • 中国
    • インド
    • 日本
    • その他アジア太平洋地域
  • その他の地域

第7章 企業プロファイル

  • Alkem Laboratories Ltd.
  • AstraZeneca plc
  • Aurobindo Pharma Ltd.
  • Cadila Healthcare Ltd.
  • Chongqing LUMMY Pharmaceutical Co., Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Glenmark Pharmaceuticals Inc.
  • Grunenthal GmbH
  • Laboratorios Saval S.A.
  • Lannett Co., Inc.
  • Mylan N.V
  • Novartis AG (Sandoz)
  • Sanofi SA
  • Stada Arzneimittel AG
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
図表

LIST OF TABLES

  • 1. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 2. GLOBAL EROSIVE ESOPHAGITIS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 3. GLOBAL GASTROESOPHAGEAL REFLUX DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 4. GLOBAL HELICOBACTER PYLORI INFECTION MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 5. GLOBAL OTHER DISEASE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 6. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 7. GLOBAL BRANDED ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 8. GLOBAL GENERIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 9. GLOBAL ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 10. GLOBAL CAPSULES & TABLETS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 11. GLOBAL INJECTIONS MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 12. GLOBAL OTHER DOSAGE TYPE MARKET RESEARCH AND ANALYSIS, 2019-2026 ($ MILLION)
  • 13. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 14. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 15. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 16. NORTH AMERICAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 17. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 18. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 19. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 20. EUROPEAN ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 21. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2019-2026 ($ MILLION)
  • 22. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 23. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 24. ASIA PACIFIC ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)
  • 25. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DISEASE, 2019-2026 ($ MILLION)
  • 26. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY TYPE, 2019-2026 ($ MILLION)
  • 27. REST OF THE WORLD ESOMEPRAZOLE MARKET RESEARCH AND ANALYSIS BY DOSAGE TYPE, 2019-2026 ($ MILLION)

LIST OF FIGURES

  • 1. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DISEASE, 2019 VS 2026 (%)
  • 2. GLOBAL ESOMEPRAZOLE MARKET SHARE BY TYPE, 2019 VS 2026 (%)
  • 3. GLOBAL ESOMEPRAZOLE MARKET SHARE BY DOSAGE TYPE, 2019 VS 2026 (%)
  • 4. GLOBAL ESOMEPRAZOLE MARKET SHARE BY GEOGRAPHY, 2019 VS 2026 (%)
  • 5. US ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 6. CANADA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 7. UK ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 8. FRANCE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 9. GERMANY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 10. ITALY ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 11. SPAIN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 12. REST OF EUROPE ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 13. INDIA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 14. CHINA ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 15. JAPAN ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
  • 16. REST OF ASIA-PACIFIC ESOMEPRAZOLE MARKET SIZE, 2019-2026 ($ MILLION)
目次
Product Code: OMR2021837

Global Esomeprazole Market Size, Share & Trends Analysis Report, By Disease (Erosive Esophagitis, Gastroesophageal Reflux Disease, Helicobacter Pylori Infection, Other), By Type (Branded and Generic), By Dosage Type (Capsules & Tablets, Injections, and Other) and Forecast, 2020-2026

The global esomeprazole market is anticipated to show a modest growth rate during the forecast period 2020-2026. Esomeprazole was first approved by the US FDA to AstraZeneca plc under the brand name Nexium. High incidences of gastroesophageal reflux disease (GERD) is one of the major factors for the growth of the market all across the globe. In 2017, esomeprazole was prescribed around 9 million times alone in the US. However, prescription numbers are reducing continuously since 2011. The presence of alternative drugs of esomeprazole is one of the major restraining factors for market growth. Omeprazole, a chemical isomer of esomeprazole is one of the most common alternatives of esomeprazole.

The global esomeprazole market is segmented based on disease, type, and dosage type. By disease, the market is further segmented into erosive esophagitis, gastroesophageal reflux disease, helicobacter pylori infection, and others. By type, the market is bifurcated into branded and generic drugs. Significant growth in the generic drug market will be witnessed during the forecast period all across the globe. By dosage type, the market is segmented into capsules & tablets, injections, and others. Capsules & tablets are expected to have a major market share during the forecast period.

By geography, the global esomeprazole market is segmented into North America, Europe, Asia-Pacific, and the Rest of the World (RoW). North America is expected to hold a considerable market share. However, significant major market growth will be witnessed in Asia-Pacific due to significant revenue generation of Nexium in Japan and China.

The esomeprazole market is consolidated in nature and a few major market players are operating in the market. Some of the major market players include AbbVie Inc, Sanofi SA, Mylan NV, Novartis AG, Teva Pharmaceutical Industries Ltd., Grunenthal GmbH, Glenmark Pharmaceuticals Inc., and Mylan N.V. The market players are adopting growth strategies including mergers & acquisitions, product approvals, and partnerships & collaborations to gain a competitive edge in the market.

Research Methodology

The market study of the global esomeprazole market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to breakdown the market in various segments; derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts to amplify the added validity of our reports.

Secondary Sources Include:

  • Financial reports of companies involved in the market
  • Authentic public databases
  • Whitepapers, research-papers, and news blogs
  • Company websites and their product catalog

The report provides an in-depth analysis of market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.

Market Segmentation:

  • Global Esomeprazole Market Research and Analysis, By Disease
  • Global Esomeprazole Market Research and Analysis, By Type
  • Global Esomeprazole Market Research and Analysis, By Dosage Type

The Report Covers:

  • Comprehensive research methodology of the Global Esomeprazole Market.
  • A detailed and extensive market overview with key analyst insights.
  • Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
  • Analysis of regional regulations and other government policies impacting the global Esomeprazole Market.
  • Insights about market determinants which are stimulating the Global Esomeprazole Market.
  • Detailed and extensive market segments with regional distribution of forecast revenues.
  • Extensive profiles and recent developments of market players.

Table of Contents

1. Report Summary

  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdowns
    • 1.2.1. By Segments
    • 1.2.2. By Geography

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Findings
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion
  • 2.3. Rules & Regulations

3. Competitive Landscape

  • 3.1. Company Share Analysis
  • 3.2. Key Strategy Analysis
  • 3.3. Key Company Analysis
    • 3.3.1. AbbVie Inc
      • 3.3.1.1. Overview
      • 3.3.1.2. Financial Analysis
      • 3.3.1.3. SWOT Analysis
      • 3.3.1.4. Recent Developments
    • 3.3.2. Sanofi SA
      • 3.3.2.1. Overview
      • 3.3.2.2. Financial Analysis
      • 3.3.2.3. SWOT Analysis
      • 3.3.2.4. Recent Developments
    • 3.3.3. Mylan NV
      • 3.3.3.1. Overview
      • 3.3.3.2. Financial Analysis
      • 3.3.3.3. SWOT Analysis
      • 3.3.3.4. Recent Developments
    • 3.3.4. Novartis AG
      • 3.3.4.1. Overview
      • 3.3.4.2. Financial Analysis
      • 3.3.4.3. SWOT Analysis
      • 3.3.4.4. Recent Developments
    • 3.3.5. Teva Pharmaceutical Industries Ltd.
      • 3.3.5.1. Overview
      • 3.3.5.2. Financial Analysis
      • 3.3.5.3. SWOT Analysis
      • 3.3.5.4. Recent Developments

4. Market Determinants

  • 4.1 Motivators
  • 4.2 Restraints
  • 4.3 Opportunities

5. Market Segmentation

  • 5.1. Global Esomeprazole Market by Disease
    • 5.1.1. Erosive Esophagitis
    • 5.1.2. Gastroesophageal Reflux Disease
    • 5.1.3. Helicobacter Pylori Infection
    • 5.1.4. Other
  • 5.2. Global Esomeprazole Market by Type
    • 5.2.1. Branded
    • 5.2.2. Generic
  • 5.3. Global Esomeprazole Market by Dosage Type
    • 5.3.1. Capsules & Tablets
    • 5.3.2. Injections
    • 5.3.3. Other ( Suspension)

6. Regional Analysis

  • 6.1. North America
    • 6.1.1. United States
    • 6.1.2. Canada
  • 6.2. Europe
    • 6.2.1. UK
    • 6.2.2. Germany
    • 6.2.3. Italy
    • 6.2.4. Spain
    • 6.2.5. France
    • 6.2.6. Rest of Europe
  • 6.3. Asia-Pacific
    • 6.3.1. China
    • 6.3.2. India
    • 6.3.3. Japan
    • 6.3.4. Rest of Asia-Pacific
  • 6.4. Rest of the World

7. Company Profiles

  • 7.1. Alkem Laboratories Ltd.
  • 7.2. AstraZeneca plc
  • 7.3. Aurobindo Pharma Ltd.
  • 7.4. Cadila Healthcare Ltd.
  • 7.5. Chongqing LUMMY Pharmaceutical Co., Ltd.
  • 7.6. Dr. Reddy's Laboratories Ltd.
  • 7.7. Glenmark Pharmaceuticals Inc.
  • 7.8. Grunenthal GmbH
  • 7.9. Laboratorios Saval S.A.
  • 7.10. Lannett Co., Inc.
  • 7.11. Mylan N.V
  • 7.12. Novartis AG (Sandoz)
  • 7.13. Sanofi SA
  • 7.14. Stada Arzneimittel AG
  • 7.15. Sun Pharmaceutical Industries Ltd.
  • 7.16. Teva Pharmaceutical Industries Ltd.